Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab PK and safety in healthy Chinese participants
NCT07142642Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2025
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thyroid eye disease (TED) comparing Teprotumumab with Placebo (2 arms). Primary endpoints: Maximum Observed Serum Concentration at 85 days, Area Under the Serum Concentration-time Curve From Time Zero to the Last Quantifiable Concentration at 85 days and 1 more. Started Aug 2025; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07142642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142642.